iBio reports fiscal Q1 2027 results, advances IBIO-600 and IBIO-610 programs
iBio completed single ascending dose testing for IBIO-600 and presented new preclinical data on IBIO-610 ahead of planned 2027 human trials.
iBio, Inc. (Nasdaq: IBIO) reported financial results for its fiscal first quarter ended September 30, 2026, in a release dated November 10, 2026, alongside a pipeline update.
The company said it finished dosing patients in the single ascending dose portion of the first-in-human Phase 1 trial of IBIO-600, its long-acting anti-myostatin antibody aimed at preserving muscle and improving body composition.1 iBio said it expects interim Phase 1 data from that single ascending dose study in the first quarter of 2027, and anticipates starting the multiple ascending dose portion of the trial in the same quarter.1
On IBIO-610, its long-acting Activin E antibody, the company presented new preclinical body composition data from obese non-human primates at the European Association for the Study of Diabetes meeting on October 1. According to iBio, by the eighth week of the study, fat made up 93% of the weight lost in primates given IBIO-610 together with semaglutide, versus 77% in those given semaglutide alone, while lean mass accounted for 6% and 22% of the weight lost in each group respectively.1 iBio said it expects to begin first-in-human trials of IBIO-610 in the first half of 2027.1 CEO Martin Brenner said the EASD data strengthen the company's conviction in IBIO-610's potential and support an IND-equivalent filing targeted for the end of 2026.1
On financials, iBio reported cash, cash equivalents and investments in debt securities of approximately $76.7 million as of September 30, 2026.1 Quarterly research and development spending rose to about $6.7 million from $3.6 million a year earlier, which the company attributed largely to increased spending on consultants and outside services supporting R&D, including the IBIO-600 Phase 1 trial, non-human primate studies and chemistry, manufacturing and controls work.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.